The Functional Repair of Neocortical Tissue (FRONT) program aims to restore brain tissue, enabling individuals with brain damage to recover cognitive functions. The program seeks to develop methods to make non-specialized cells form into normal tissue. After these cells are grafted, FRONT will measure how well they integrate with the surrounding healthy neocortex tissue, proper layered structure of normal cortical tissue, and functional recovery. The goal of the program is to alleviate the personal and financial burdens of previously ‘permanent’ brain damage.
Supports promising research that has high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the fiscal year 2025 (FY25) Breast Cancer Research Program (BCRP) overarching challenges, unless adequate justification for exception is provided. Applications must address the challenge in a way that can lead to or make a breakthrough and have major impact. The FY25 Breakthrough Award mechanism contains three different funding levels designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. The current program announcement discusses the Breakthrough Award Levels 1 and 2.
The fiscal year 2025 (FY25) Breast Cancer Research Program (BCRP) Clinical Research Extension Award aims to extend or expand the data collection, follow-up, and analysis of breast cancer clinical studies. The intent of this award mechanism is to increase the clinically relevant impact of breast cancer patient participation in clinical research by addressing the knowledge lost due to early trial termination, limited patient follow-up, or suboptimal sample and/or data collection and analysis. All applications must address at least one of the FY25 BCRP overarching challenges, unless adequate justification for exception is provided.
PCORI uses the Orphan Drug Act definition of a rare disease, defined as a condition that affects fewer than 200,000 individuals in the United States. Though each disease is rare individually, it is estimated that there are more than 10,000 rare diseases affecting about 30 million Americans. People with many different types of rare diseases and their caregivers often experience similar challenges such as finding reliable information and relevant resources, receiving an accurate diagnosis, and gaining access to adequate and appropriate care. This PFA will solicit applications proposed to address patient-centered CER questions that will fill important rare disease research gaps. Applications addressing critical decisional dilemmas that span multiple rare diseases are encouraged.
This PCORI Funding Announcement (PFA) invites applications for high-impact patient-centered comparative clinical effectiveness research (CER) projects.
PCORI’s Research Project Agenda includes a set of Topic Themes that are included in this funding opportunity and further detailed below. Applicants have the option to choose up to three Topic Themes within the Research Project Agenda based on how their proposed research aligns with the themes. However, aligning with a Topic Theme is not required. The Topic Themes will assist PCORI in determining the optimal review pathway for the proposed research.
This PCORI Funding Announcement (PFA) invites applications for high impact patient-centered comparative clinical effectiveness research (CER) projects that will address critical decisions faced by patients, families, caregivers, clinicians, and the health and healthcare community and for which there is insufficient evidence.
Investigators must propose an individual-level or cluster randomized controlled trial of significant scale and scope for this PFA. The proposed trials should address critical decisional dilemmas that require important new evidence about the comparative clinical effectiveness of available interventions. Proposed studies should compare interventions that already have robust evidence of efficacy and are in current use. If efficacy is not well established, then widespread use must be documented. Clinical interventions (such as medications, diagnostic tests, or procedures) and delivery system interventions (such as workforce, technologies and healthcare service delivery designs) are appropriate for these studies.
This PCORI Funding Announcement (PFA) seeks to fund studies that build an evidence base on engagement in research, including:
To learn more about PCORI's priorities in measures of engagement, please see the article available at Measuring What Matters for Advancing the Science and Practice of Engagement.
With this PCORI Funding Announcement (PFA), PCORI aims to fund studies that address high-priority methodological gaps in patient-centered comparative clinical effectiveness research (CER).
For the Cycle 3 2025 Methods PFA, PCORI has identified the following areas that address important methodological gaps and lead to improvements in the strength and quality of evidence generated by CER studies:
This PCORI Funding Announcement (PFA) seeks to fund implementation projects that promote the uptake of peer-reviewed findings from specific, high-priority, PCORI-funded patient-centered comparative clinical effectiveness research (CER) in the context of the body of related evidence. This PFA is an open competition opportunity for principal investigators to propose implementation projects that move evidence toward practical use in improving health care and health outcomes. Applicants may propose projects with budgets up to $2.5 million in direct costs.